Clinical and economic impact of COVID-19 on people with obesity in a Spanish cohort during the first pandemic peak

Frontiers in Endocrinology

Endocrinology

Poyato F¹  Nuñez A²  Rubio-Herrera MA³  Martín V⁴  Fuentes-Ferrer ME⁵  González López-Valcárcel B⁶  Barber-Pérez P⁶  Santucci C⁷  Luaces M⁸  Torrego-Ellacuría M⁹  González-Pérez C^1,10 

[1] Department of Clinical, Medical and Regulatory, Novo Nordisk Pharma, Sociedad Anònima (SA.), Madrid, Spain;Department of Critical Care, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain;Department of Endocrinology and Nutrition, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain;Department of Medicine, Faculty of Medicine, Universidad Complutense de Madrid, Madrid, Spain;Department of Market Access and Public Affairs, Novo Nordisk Pharma, Sociedad Anónima (SA.), Madrid, Spain;Department of Preventive Medicine, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain;Research Unit, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain;Department of Quantitative Methods for Economics and Management, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain;Department of Quantitative Methods for Economics and Management, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain;Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy;Innovation Unit, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain;Innovation Unit, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain;Department of Endocrinology and Nutrition, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain;Innovation Unit, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain;Department of Hospital Pharmacy, Hospital Clínico San Carlos, Instituto de Investigaciòn Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain;

关键词: COVID-19;    obesity;    invasive mechanical ventilation (IMV);    intensive care unit (ICU);    economic burden;    obesity comorbidities;    diabetes mellitus;   

DOI  :  10.3389/fendo.2023.1146517

 received in 2023-01-17, accepted in 2023-05-09,  发布年份 2023

来源: Frontiers

【 摘 要 】

IntroductionCOVID-19 and obesity relationship has been extensively studied since the COVID-19 outbreak, proving obesity is a risk factor. This study aims to broaden the available information about this association and to evaluate the economic impact of obesity and the COVID-19 disease combination.MethodsThis retrospective study analyzed a sample of 3,402 patients admitted to a Spanish hospital with available body mass index (BMI) data.ResultsThe prevalence of obesity was 33.4%. Patients with obesity showed a higher risk of hospitalization (OR 95% ConfidenceInterval [CI]=1.46; [1.24-1.73]; p < 0.001), which increased with the obesity degree (I: OR [95% CI]=1.28 [1.06-1.55], p =0.010; II: OR [95% CI]=1.58 [1.16-2.15], p =0.004; III: OR [95% CI] =2.09 [1.31-3.34], p =0.002). Patients with type III obesity had a significantly higher risk of intensive care unit (ICU) admission (OR [95% CI]= 3.30 [1.67-6.53]; p = 0.001) and invasive mechanical ventilation (IMV) need (OR [95% CI]= 3.98 [2.00-7.94]; p<0.001). The average cost per patient was remarkably higher in patients with obesity (p = 0.007), reaching an excess cost of 28.41% in the study cohort and rising to 56.5% in patients < 70 years. The average cost per patient increased significantly with the degree of obesity (p = 0.007).DiscussionIn conclusion, our results suggest a strong association between obesity and adverse COVID-19 outcomes and higher expenditures in patients with both conditions.

【 授权许可】

Unknown   
Copyright © 2023 M, MA, B, ME, V, F, P, C, A, C and M